While you're collecting healthy dividends, you'll also benefit from the price-to-earnings (P/E) ratio expanding when revenue ...

Option traders moderately bearish in Pfizer (PFE), with shares down 32c near $24.89. Options volume relatively light with 88k contracts traded and ...

Built into the 2026 guidance is a $1.5 billion decline in sales of its COVID products—from an estimated $6.5 billion this ...

Pfizer PFE expects a significant negative impact on revenues from the loss of exclusivity (“LOE”) of several of its key ...

Pfizer signaled Tuesday it expects a challenging 2026 as it invests in new products to offset declines in Covid-19 revenues ...

Pfizer shares have emerged as a compelling contrarian investment opportunity as the pharmaceutical giant trades at historically attractive valuations following an extended period of market skepticism.

Discover why Pfizer (PFE) remains a compelling income opportunity with a 7% yield, robust cash flow, and long-term growth ...

The drop reflects investors reactions to Pfizer’s new 2026 revenue forecasts, which is set to be between the range of $59.5 ...

Pfizer Inc. (NYSE:PFE)’s shares are down by 5.90% year-to-date, and December has been a tumultuous month for them.

Pfizer stock offers 30% upside with strong non-COVID franchises, margin expansion, and pipeline potential. Click here to read my latest analysis of PFE stock.

In the second quarter, Pfizer reported adjusted diluted earnings per share of $0.78 on revenue of nearly $14.7 billion. Both numbers came in well above expectations, with diluted EPS $0.20 higher than ...

Looking at the universe of stocks we cover at Dividend Channel, in trading on Tuesday, shares of Pfizer Inc (Symbol: PFE) were yielding above the 7% mark based on its quarterly dividend (annualized to ...